Clinical Trials Using Lapatinib Ditosylate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Lapatinib Ditosylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-9 of 9
  • Whole-Brain Radiation Therapy or Stereotactic Radiosurgery with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer

    This randomized phase II trial studies how well whole-brain radiation therapy or stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called human epidermal growth factor receptor 2 (HER2) on its cells and has spread to the brain. Radiation therapy uses high energy x rays to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether whole-brain radiation therapy or stereotactic radiosurgery together with lapatinib ditosylate is an effective treatment for brain metastasis from breast cancer.
    Location: 270 locations

  • Intermittent High-Dose Lapatinib Ditosylate and Capecitabine in Treating Patients with HER2 / Neu Positive Breast Cancer with Central Nervous System Metastases

    This phase I trial studies the side effects and best dose of lapatinib ditosylate when given together with capecitabine in treating patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to the central nervous system. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lapatinib ditosylate and capecitabine may kill more tumor cells.
    Location: 7 locations

  • Temozolomide and Lapatinib Ditosylate in Treating Patients with Recurrent Low-Grade Ependymoma

    This phase II trial studies how well temozolomide and lapatinib ditosylate work in treating patients with low-grade ependymoma that has come back (recurrent). Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Giving temozolomide and lapatinib ditosylate together may kill more tumor cells.
    Location: 6 locations

  • Lapatinib Ditosylate before Surgery in Treating Patients with Recurrent High-Grade Glioma

    This pilot clinical trial studies how well lapatinib ditosylate before surgery works in treating patients with high-grade glioma that has come back after a period of time during which the tumor could not be detected. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 9 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.
    Location: 2 locations

  • Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of lapatinib ditosylate when given together with dabrafenib in treating patients with thyroid cancer that cannot be removed by surgery and has not responded to previous treatment. Dabrafenib and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients with HER2-Positive Metastatic Breast Cancer

    This phase II trial studies how well capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine and cyclophosphamide daily may kill more tumor cells. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab together may be an effective treatment for breast cancer.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Lapatinib Ditosylate, Temozolomide, and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme

    This phase II clinical trial studies the side effects and to see how well it works when giving lapatinib ditosylate, temozolomide, and radiation therapy together in treating patients with newly diagnosed glioblastoma multiforme. Lapatinib ditosylate may top the growth of tumor cells by blocking some of the enzymes needed for cell growth. Temozolomide may slow the growth of tumor cells. Radiation therapy uses high energy beams to kill tumor cells and shrink tumor. Giving lapatinib ditosylate, temozolomide, and radiation therapy together may be a better treatment for patients with newly diagnosed glioblastoma multiforme.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Lapatinib Ditosylate Concentration and Activity within Tumors in Patients with Neurofibromatosis Type 2 or Acoustic Schwannoma Undergoing Surgery

    This pilot clinical trial studies the concentration and activity of lapatinib ditosylate within tumors in patients with neurofibromatosis type 2 or acoustic schwannoma who are undergoing surgery. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland